News

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the…

6 days ago

Renovaro Enters into a Strategic Collaboration with Nebul to Advance a Paradigm Shift for Early Disease Detection

Renovaro will Establish the GEDi CUBE Next Generation Nvidia Blackwell Cluster with Nebul's certified AI Healthcare Cloud solutions LOS ANGELES,…

6 days ago

HWH International Inc. and Sharing Services Global Corporation see opportunity in Robotics

BETHESDA, MD, Dec. 20, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. (“HWH”) (Nasdaq: HWH) and its partner Sharing Services Global…

6 days ago

Light-it Group Launches Enlighten Ventures: A Micro-VC Initiative to Propel Healthtech Innovation

Javier Lempert (CTO & Founder), Alan Brande (CEO & Founder) and Martin Oppenheimer (COO & Founder) at Light-it’s HQ. AVENTURA,…

6 days ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Funds expected to be used to advance IO Biotech’s immune-modulating therapeutic cancer vaccines, including potential BLA submission for IO102-IO103 in…

6 days ago

Alignment Healthcare to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ORANGE, Calif. , Dec. 20, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present…

6 days ago

Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia

FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical…

6 days ago

Commure Acquires Memora Health, a Digital Care Navigation Platform, to Enhance Intelligent Care Navigation

MOUNTAIN VIEW, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Commure, a leading healthcare technology company, announced today the acquisition of…

6 days ago

RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial

Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric…

6 days ago

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value < 0.05) in development of esophageal varices in…

6 days ago